Skip to Content

Tilray Brands Inc TLRY

Morningstar Rating
$2.46 −0.03 (1.01%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

First Pillar of Germany's Cannabis Legalization Begins April 1; Legal Sales to Come Later

The Bundestag, the lower house of Germany’s legislature, passed a cannabis bill last month that would allow possession of up to 25 grams and home-growing of up to three plants. The law will become effective April 1 as planned after the Bundesrat, the upper house, voted not to send it to mediation committee on March 22. The law expands on July 1 to allow nonprofit cannabis grow clubs of up to 500 members and 50 grams per member.

Price vs Fair Value

TLRY is trading at a 31% discount.
Price
$2.15
Fair Value
$9.70
Uncertainty
Very High
1-Star Price
$2.81
5-Star Price
$5.23
Economic Moat
Nmz
Capital Allocation
Trqhynzsl

Bulls Say, Bears Say

Bulls

Tilray's better financial health and profitability lead compared with Canadian peers positions it to dominate its home market.

Bears

The existence of the illicit market limits the potential price increases Tilray can push through to consumers.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLRY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.48
Day Range
$2.402.63
52-Week Range
$1.513.40
Bid/Ask
$2.45 / $2.46
Market Cap
$1.85 Bil
Volume/Avg
45.6 Mil / 27.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.40
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
1,600

Competitors

Valuation

Metric
TLRY
CRON
ACB
Price/Earnings (Normalized)
Price/Book Value
0.540.940.58
Price/Sales
2.4011.790.84
Price/Cash Flow
Price/Earnings
TLRY
CRON
ACB

Financial Strength

Metric
TLRY
CRON
ACB
Quick Ratio
0.8921.681.79
Current Ratio
1.6322.543.79
Interest Coverage
−24.18
Quick Ratio
TLRY
CRON
ACB

Profitability

Metric
TLRY
CRON
ACB
Return on Assets (Normalized)
−1.87%−0.53%
Return on Equity (Normalized)
−2.39%−0.55%
Return on Invested Capital (Normalized)
−1.58%−4.90%
Return on Assets
TLRY
CRON
ACB
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class ACtljhcmpXltq$77.2 Bil
MKKGY
Merck KGaA ADRNljjkgqfjLwpdyl$75.4 Bil
HLN
Haleon PLC ADRNwltctxtmCyjq$38.1 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRHbnbbghkFffls$16.0 Bil
VTRS
Viatris IncSrfcftsjFss$14.0 Bil
RDY
Dr Reddy's Laboratories Ltd ADRYrbcvchrsLdzr$12.1 Bil
CTLT
Catalent IncLzslxyxgcPzpkwg$10.2 Bil
PRGO
Perrigo Co PLCGtspxprBlvz$4.3 Bil
CURLF
Curaleaf Holdings IncFxzstljzGcfz$4.0 Bil
PBH
Prestige Consumer Healthcare IncVzhdyxxmGqxwc$3.6 Bil

Sponsor Center